Oppenheimer Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $35

Benzinga · 10/16 09:12
Oppenheimer initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $35.